Biocryst Pharmaceuticals (BCRX) Non Operating Interest Expenses (2011 - 2026)

For the trailing twelve months through Jun 30, 2026, Non Operating Interest Expenses at Biocryst Pharmaceuticals was $75.29 million, down 20.2% year-over-year; for FY2025, it was $78.87 million, down 19.9% from FY2024.

• Annual Non Operating Interest Expenses shows a five-year compound annual growth rate of 40.3% (FY2020 to FY2025).
• In prior years, Biocryst Pharmaceuticals' Non Operating Interest Expenses was $98.52 million in FY2024 (-9.0%), $108.24 million in FY2023 (+9.2%), $99.09 million in FY2022 (+67.1%) and $59.29 million in FY2021 (+308.9%).
• The Q2 2026 figure stands as the highest quarterly Non Operating Interest Expenses since Q1 2025.
• On a year-over-year basis, Non Operating Interest Expenses increased in 1 of the last eight quarters, with an average decline of 13.1%.
• The strongest year-over-year quarter for Non Operating Interest Expenses in the past five years was Q3 2021, with growth of 382.2%; the weakest was Q4 2025, with a decline of 42.2%.
• According to Business Quant data, Non Operating Interest Expenses for the three prior quarters was $19.78 million (Q1 2026), $14.14 million (Q4 2025) and $19.66 million (Q3 2025).